Aignostics is an international, interdisciplinary team powering the next generation of precision medicine and advancing the fields of AI and pathology. Founded in 2018 as a spin-off from Charité Berlin, one of Europe's largest university hospitals, the company combines proprietary access to multimodal clinical datasets, industry-leading AI technologies, and rigorous science to deliver transformative insights for precision medicine.

With offices in Berlin and New York, Aignostics supports drug discovery, translational research, clinical trials, and companion diagnostics development across multiple therapeutic areas. Their mission is to transform drug development and improve patient outcomes using AI-driven novel insights for precision medicine.

Aignostics offers rigorously developed products such as Pathology Foundation Models and the Atlas H&E-TME profiling product. They provide custom services for complex image and data analysis through the drug discovery process and clinical applications, including Target & Biomarker Discovery, Translational Research, and Digital Diagnostics.

The company values fairness, honesty, humility, diversity, equity, and inclusion. They foster a collaborative environment where computational expertise meets biological understanding. Aignostics is mission-driven and dedicated to positive impact in healthcare, emphasizing teamwork, idea meritocracy, and sustainable high performance.

Located primarily at Alt-Moabit 73, Berlin, Germany, they have a diverse leadership team with deep functional competency in data science, engineering, pathology, and business development.